Evidence map›Paper›PMID 37008088›Full record

ArticleACS omega2023

Industrial Manufacture of Enteric Hard Capsules Using Novel Formulations Based on Hypromellose Phthalate/Gelatin and Investigation of Pantoprazole Release.

Ramin Ramezani Kalmer, Mohsen Mohammadi Haddadan, Maryam Azizi, Mojgan Ghanbari, Dariush Samandarian, Atefeh Sadjadinia, Hamed Ramezanalizadeh, Afzal Karimi, Mortaza Golizadeh

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ramin Ramezani KalmerIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.
Mohsen Mohammadi HaddadanIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.
Maryam AziziIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.
Mojgan GhanbariIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.ORCID https://orcid.org/0000-0003-1192-4471
Dariush SamandarianIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.
Atefeh SadjadiniaIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.
Hamed RamezanalizadehIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.
Afzal KarimiIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.
Mortaza GolizadehIran Gelatin Capsule Mfg Co., Tehran 3351773415, Iran.
Iran University of Medical Sciences · IRSharif University of Technology · IRUniversity of Kashan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Capsules are popular oral dosage forms because of their ease of production. They are widespread pharmaceutical products. Hard capsules are preferred dosage forms for new medicines undergoing clinical tests because they do not require expansive formulation development. Functional capsules with built-in gastroresistance, aside from the traditional hard-gelatin or cellulose-based vegetarian capsules, would be beneficial. In this research, the effect of polyethylene glycol-4000 (PEG-4000) was investigated on the formulation of uncoated enteric hard capsules based on hypromellose phthalate (HPMCPh) and gelatin. Three different formulations based on HPMCPh, gelatin, and PEG-4000 were tested to achieve the optimal formulation for the industrial production of hard enteric capsules with desired physicochemical and enteric properties. The results reveal that the capsules containing HPMCPh, gelatin, and PEG-4000 (F1) are stable in the stomach environment (pH = 1.2) for 120 min, and during this time, no release happens. The outcomes also demonstrate that PEG-4000 blocks the pores and improves enteric hard capsule formulation. In this research, we present a specific procedure for manufacturing uncoated enteric hard capsules on an industrial scale that does not require an extra coating step for the first time. The industrial-scale validated process can considerably reduce the cost of manufacturing standard enteric-coated dosage forms.

Identifiers

PMID37008088
PMCPMC10061655
OpenAlexW4327631843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.